Supplementary Table S6 from T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma

2026 Open access

Read full text

Authors: Robin K. Kelley, Young June Lee, James Conway, John F. Kurland, Patricia E. Mccoon

DOI: 10.1158/1078-0432.31353166

Cited by: 0

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Hepatocellular Carcinoma Treatment and Prognosis Hepatitis B Virus Studies